Learn All CategoriesAlzheimer’s disease(8)Article(9)Education(10)Epidermolysis Bullosa(1)events(2)Glaucoma(2)Macular Degeneration(4)presentation(4)Rare cannabinoids(5)Uncategorised(112)Webinar(3) All TagsAlzheimer’s disease(1)Article(1)videos(1) Article: InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular DegenerationJuly 25, 2024Read More InMed’s INM-901 for Alzheimer’s Disease – Preclinical Data SummaryJuly 25, 2024Read More Article: InMed’s INM-901 Demonstrates Potential as a Multi-factorial Approach to Treating Alzheimer’s DiseaseJuly 22, 2024Read More InMed Presents at Benzinga’s Healthcare and Biotech BreakthroughsJuly 2, 2024Read More Replay: InMed Presents at Emerging Growth ConferenceJune 14, 2024Read More Article: InMed Pharmaceuticals Inc. (NASDAQ: INM) Advances Therapies Targeting Degenerative DiseasesJune 14, 2024Read More Video Presentation: InMed’s INM-901 is a Potential Multi-factorial Approach to Treating Alzheimer’s DiseaseJune 12, 2024Read More The Dales Report: InMed Pharmaceuticals and Alzheimer’s ResearchMay 28, 2024Read More Drug Discovery Online Article: Cannabinoids Show Promise As New Treatment For Alzheimer’s DiseaseMay 21, 2024Read More What is Age-related Macular Degeneration? Does AMD Cause Blindness?May 21, 2024Read More InMed Presents at Webull Biotech Investment WebinarMay 16, 2024Read More Benzinga: InMed (NASDAQ: INM) Developing Cannabinoids Analogs To Treat Alzheimer’s – New Studies Showcase INM-901’s Therapeutic AbilitiesMay 6, 2024Read More 12345678910111234567891011 Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP